VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

GU Cancers 2021 | Extended follow-up data from POUT in urothelial cancer

Robert Jones, MD, PhD, University of Glasgow & Beatson West of Scotland Cancer Centre, Glasgow, UK, provides a summary of the updated outcome data presented at ASCO GU 2021 from the randomized Phase III POUT study (NCT01993979) of peri-operative gemcitabine-cisplatin chemotherapy versus surveillance in upper tract urothelial cancer (UTUC). The extended follow-up data indicated that the previously reported disease-free survival benefit was maintained, although no statistically significant improvement in overall survival was observed. This interview took place during the 2021 Genitourinary Cancers Symposium.

Transcript (edited for clarity)

POUT is another UK National Cancer Research Institute trial. And this is a trial which we already know the primary results from. So, this was a trial of adjuvant chemotherapy in patients who’d undergone nephroureterectomy for T2 or above upper tract urothelial cancer. The primary end point of the trial was progression-free survival, and we already know that the trial had met that primary objective and was positive and so it’s already changed practice but this was the extended follow-up...

POUT is another UK National Cancer Research Institute trial. And this is a trial which we already know the primary results from. So, this was a trial of adjuvant chemotherapy in patients who’d undergone nephroureterectomy for T2 or above upper tract urothelial cancer. The primary end point of the trial was progression-free survival, and we already know that the trial had met that primary objective and was positive and so it’s already changed practice but this was the extended follow-up. In particular, we wanted to follow up the trial until we’d achieved a number of death events. Unfortunately, although there was a trend, there was no statistically significant overall survival gain with adjuvant chemotherapy in this context. It’s still a positive trial. This is a secondary end point and the primary end point findings were maintained in this study.

Read more...

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter